| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.094 | 0.04 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.07 | 0.04 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.16 | 0.04 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.067 | 0.04 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.068 | 0.04 |